Omnihealth Practice

Baricitinib maintains safety profile over 4.6 years in final BREEZE-AD trials analysis

Baricitinib is a selective Janus kinase inhibitor approved in over 70 countries for treating moderate-to-severe atopic dermatitis (AD) in adults.1 In the European Union, Saudi Arabia, and Japan, it is also approved for children and adolescents aged 2 years and older with moderate-to-severe AD who ar

DERMATOLOGY

09 Jan 2025

Digital health program reduces AD symptoms and scratching in real-world study

Symptoms of atopic dermatitis (AD), including dry skin, pruritus, and skin lesions, significantly impact the quality of life (QoL) of patients.¹ At the EADV Congress 2024, results from a real-world use of a 12-week digital health program developed to help patients with AD build healthy habits around the itch-scratch cycle, were presented by Dr. Sigrídur Lára Gudmundsdóttir from Sidekick Health, Kopavogur, Iceland.¹

DERMATOLOGY

09 Jan 2025

Dupilumab reduces the use of OCS and antibiotics in patients with CRSwNP in real-world practice

STUDY DESIGN Dupilumab is indicated as an add-on maintenance treatment for adult patients with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP).¹ It has been shown to improve both objective and patient-reported outcomes in this population.1 However, data on dupilumab’s eff

RESPIROLOGY

13 Dec 2024

Evaluation of cancer risks in IIM: A Hong Kong perspective on IMACS stratification

Idiopathic inflammatory myopathies (IIM) is a group of autoimmune disorders characterized by chronic muscle inflammation, presenting with varying clinical features, treatment responses, and prognoses.¹ Recently, the International Myositis Assessment and Clinical Studies Group (IMACS) released a set

RHEUMATOLOGY ONCOLOGY

30 Oct 2024

Dr. So, Ho

Assistant Professor,
Division of Rheumatology,
Department of Medicine and Therapeutics,
Faculty of Medicine,
The Chinese University of Hong Kong

Dr. Tang, Yan-Ki Iris

Clinical Assistant Professor of Practice,
Department of Medicine,
Li Ka Shing Faculty of Medicine,
The University of Hong Kong

Redefining the management of non-muscle-invasive bladder cancer in one swoop with en bloc resection over standard transurethral resection

Bladder cancer is one of the most prevalent cancers worldwide, with non-muscle-invasive bladder cancer (NMIBC) accounting for 75% of bladder cancer cases. While the standard piecemeal transurethral resection of bladder tumor (SR) has been the conventional surgical procedure for NMIBC, oncological control remains subpar, prompting the development of alternative techniques such as en bloc transurethral resection of bladder tumor (ERBT). To examine the impact of ERBT on the prognosis of NMIBC, Professor Teoh, Yuen-Chun Jeremy and his team conducted a local phase 3 randomized controlled trial, EB-StaR, that compared the 1-year recurrence rate of NMIBC with ERBT to SR. In an interview with Omnihealth Practice, Prof. Teoh discussed the implications of the results and the future of ERBT implementation.

ONCOLOGY UROLOGY

06 Aug 2024

Professor Teoh, Yuen-Chun Jeremy

Associate Professor,
Department of Surgery,
Faculty of Medicine,
The Chinese University of Hong Kong

ERS 2024

September 7-11, 2024 | Vienna, Austria

Bilateral lung transplants offer comparable survival to heart-lung transplants in PAH patients

Pulmonary arterial hypertension (PAH) patients referred for transplant typically have an inadequate response to guideline-directed therapies, are at intermediate-to-high risk of death (with 1-year mortality exceeding 10%), or have conditions like pulmonary capillary hemangiomatosis (PCH) or pulmonar

30 Oct 2024

ASCO 2024

May 31-Jun 4, 2024 | Chicago, United States

Phase 3 PhALLON trial reveals high rates of MRD negativity at any time and prolonged PFS with ponatinib in patients with newly diagnosed Ph+ ALL

STUDY DESIGN Ponatinib is a third-generation BCR::ABL tyrosine kinase inhibitor (TKI) that inhibits BCR::ABL1 regardless of any single resistance mutations, including T315I. It was previously evaluated in the PhALLCON (ponatinib-3001) trial in adults with newly diagnosed Philadelphia chromosome-po

HEMATOLOGY ONCOLOGY

12 Sep 2024

Improved outcomes with FLOT perioperative chemotherapy vs. CROSS neoadjuvant chemoradiation for esophageal cancer: The ESOPEC Trial

The incidence of esophageal adenocarcinoma (EAC) is increasing, particularly in high-income countries, with almost 86,000 new cases globally in 2020.1 While surgery is the mainstay for cure in non-metastatic disease, multimodality treatment can improve survival in these patients.1 For early-stage tu

GASTROENTEROLOGY & HEPATOLOGY

05 Aug 2024

Limited efficacy of prothrombin complex concentrate in managing DOAC-associated ICH

Direct oral anticoagulants (DOACs) have revolutionized the management of atrial fibrillation (AF), significantly reducing the risk of ischemic stroke.1 However, the associated risk of intracerebral hemorrhage (ICH), though rare, remains a serious concern with high mortality rates.2 To mitigate the i

NEUROLOGY

03 Oct 2024

Local retrospective study finds lower risk of acute kidney injury in ICU patients with COVID-19 vs. seasonal influenza

Influenza and COVID-19 are the most common respiratory viral infections among intensive care unit (ICU) patients, which can result in multiple organ failures requiring intensive support.1 Acute kidney injury (AKI) is a frequent complication in critically ill patients with these infections.1 To inves

INFECTIOUS DISEASE

24 Sep 2024

Tirzepatide demonstrates improvements in HF outcomes in patients with HFpEF and obesity

Heart failure with preserved ejection fraction (HFpEF) accounts for over half of all heart failure (HF) cases, many of whom are either overweight or obese.1 Despite the growing prevalence of patients with both conditions, treatment options remain scarce.1 Tirzepatide, a once-weekly, dual glucose-dep

CARDIOLOGY

27 Sep 2024

Lasting protection from recurrence: A case sharing of high-risk HR+ HER2- EBC management with abemaciclib

Abemaciclib was the first cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor to demonstrate a significant improvement in invasive disease-free survival (IDFS) in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) early breast cancer (EBC).¹ In an interview with Omnihealth Practice, Dr. Hui, Cheng-Vai cited data from large-scale clinical trials including monarchE, describing the long-term efficacy and tolerable safety profile of the 2-year fixed-duration abemaciclib treatment, even in populations who had received dose reductions. Dr. Sumou, Ingrid Karmane also shared her experience using abemaciclib in a case of an HR+ HER2- EBC patient with a high risk of recurrence, outlining the efficacy of the treatment and how its tolerability profile can be managed. Additionally, they highlighted the importance of patient education and close follow-up by a multi-disciplinary team to enhance treatment outcomes.

ONCOLOGY OBSTETRICS & GYNECOLOGY

20 Sep 2024

Dr. Hui, Cheng-Vai

Consultant in Medical Oncology,
Macau Oncology Association

Dr. Sumou, Ingrid Karmane

Medical Oncologist,
Macau Oncology Association

Sequencing retreatment with anti-CD38 mAb in heavily pretreated RRMM patients

Patients with multiple myeloma (MM) are highly susceptible to developing relapsed and refractory (RR) disease towards lenalidomide and proteasome inhibitors (PIs) and require new active treatments at relapse. As such, novel treatment options like isatuximab, a monoclonal antibody (mAb) that targets

HEMATOLOGY

06 Mar 2024

Professor Yong, Kwee

University College London,
United Kingdom

Every update. In your inbox.

Get access to our exclusive articles.

Overseeing local ocular health with a watchful gaze: Consensus on managing center-involving DME in Hong Kong

Diabetic macular edema is a prevalent cause of vision loss among individuals in the working-age population, characterized by the disruption of the blood-retinal barrier and the accumulation of fluid and serum macromolecules in the intercellular space. As the incidence of diabetes mellitus

OPHTHALMOLOGY

02 Jul 2024

Refining the management of hyperkalemia in the Asia-Pacific region: Consensus statements from a multidisciplinary expert panel

Hyperkalemia, defined as serum potassium >5.0mmol/L, is a potentially lethal condition as it hinders muscle function and myocardial excitability, which may contribute to arrhythmias and sudden cardiac deaths. Epidemiological data suggests the global prevalence of hyperkalemia is around 6.3%, but the

NEPHROLOGY

20 Jun 2024

Nephrology. 2024

Yap YHD, Ma CWR, Wong CKE, Tsui SHM, Yu YTE, Yu V, Szeto CC, Pang WF, Tse HF, Siu CDW, Tan CBK, Chen WCW, Li CL, Chen W, Chan TM. Consensus statement on the management of hyperkalaemia—An Asia-Pacific perspective. Nephrology. 2024;29(6):311-324.

Case Sharing: Early dapagliflozin stabilizes patients with acute decompensated heart failure regardless of ejection fraction

HF is a complex condition characterized by pathophysiologic heterogeneity and the presence of congestive symptoms, particularly in cases of acute decompensated heart failure (ADHF). These factors significantly increase the risk of hospitalization due to HF worsening and CV death.

CARDIOLOGY

25 Sep 2024

Dr. Fong, Yan-Hang Esmond

Specialist in Cardiology

Case sharing: Improving treatment outcome in MDD patients with timely brexpiprazole augmentation

Treatment-resistant depression (TRD) is defined as treatment failure following ≥2 trials of antidepressant therapy (ADT) at adequate doses, duration and adherence.1 Around 30% of patients with major depressive disorder (MDD) become resistant to conventional treatments.2 TRD is independently associa

PSYCHIATRY

09 May 2024

Dr. Lai, Chi-Lun

Specialist in Psychiatry

Harnessing the potential of deucravacitinib in the treatment of psoriasis: A case series of real-world clinical applications

DERMATOLOGY

20 Nov 2024

Professor Chan, Hin-Lee Henry Honorary

Clinical Professor,
Division of Dermatology,
Department of Medicine,
he University of Hong Kong Specialist in Dermatology and Venereology

Professor April Armstrong

Professor and Chief of Dermatology,
University of California Los Angeles

Dr. Guan, Xin

Professor and Associate Chief Physician of Dermatology,
Peking University Third Hospital

Evolving insights in Asian R/M NPC care: A case sharing of tislelizumab

ONCOLOGY

03 Dec 2024

Dr. Sumou, Ingrid Karmane

Medical Oncologist,
Macau Oncology Association

Infographics

OBSTETRICS & GYNECOLOGY PSYCHIATRY CARDIOLOGY

Heartfelt Connections: The Shadow of PND on Maternal CV Health

03 Dec 2024

OPHTHALMOLOGY NEPHROLOGY

Insight into CKD progression: Ophthalmalogical outcomes and eGFR in non-diabetic CKD

21 Jun 2024

CARDIOLOGY

CKD or No CKD: Knocking down CV risks with rosuvastatin

08 Jul 2024

NEUROLOGY

Longitudinal assessment of MCI and dementia in an essential tremor cohort

08 Jul 2024

HEMATOLOGY

From bridging to maintenance: A case of gilteritinib in RR FLT3 AML patients undergoing HSCT

09 May 2024

NEUROLOGY

Real-world effectiveness of fremanezumab in migraine prevention

08 Apr 2024

HEMATOLOGY CARDIOLOGY

Incidence of anemia with long-term low-dose aspirin

18 Mar 2024

Decoding the spectrum of tolerance in fish allergies

04 Jan 2024

DIABETES & ENDOCRINOLOGY CARDIOLOGY

Earlier and higher risk of CVD with a younger T2D diagnosis

04 Jan 2024

DIABETES & ENDOCRINOLOGY

U-shaped relationship between sleep duration and T2DM regardless of traditional lifestyle risk factors

17 Nov 2023

RESPIROLOGY

Brain Gliosis: A Potential Origin of Persistent Post-COVID-19 Depressive and Cognitive Symptoms

17 Nov 2023

DIABETES & ENDOCRINOLOGY NEUROLOGY

The nuanced link between prediabetes and dementia

23 Aug 2023

NEUROLOGY RHEUMATOLOGY

Connecting the dots between Parkinson’s disease and rheumatoid arthritis

12 Jul 2023

CARDIOLOGY PEDIATRICS

Cardio-oncology monitoring in pediatric populations - Delphi consensus recommendations from an Australian and New Zealand expert group

28 Apr 2023

RESPIROLOGY

Targeting TSLP for severe asthma - Tezepelumab updates from the 2023 American Academy of Allergy Asthma & Immunology Annual Meeting

06 Apr 2023

HEMATOLOGY PEDIATRICS

A new way out for alpha thalassemia major - Give them a chance at life with In-utero transfusions

15 Mar 2023

RESPIROLOGY

Beware of overlapping phenotypes in severe asthma: The eosinophilia and IgE double whammy

27 Feb 2023

NEPHROLOGY

Stay on the path of treatment - Take on a high-K with ease
ASN abstract highlight on sodium zirconium cyclosilicate and hyperkalemia

23 Feb 2023

RESPIROLOGY

Real-world effectiveness of benralizumab around the globe

06 Dec 2022

RESPIROLOGY

Remission is within reach - Target the underlying drivers of inflammation with benralizumab

19 Sep 2022

ONCOLOGY RESPIROLOGY

PACIFIC-6: Durvalumab after CRT showed similar safety profile as the PACIFIC regimen with encouraging efficacy data in frailer and older patients with stage 3, unresectable NSCLC